Grading obstructive lung disease using tomographic pulmonary scintigraphy in patients with chronic obstructive pulmonary disease (COPD) and long-term smokers by unknown
ORIGINAL ARTICLE
Grading obstructive lung disease using tomographic pulmonary
scintigraphy in patients with chronic obstructive pulmonary
disease (COPD) and long-term smokers
Marika Bajc • Hanna Markstad • Linnea Jarenba¨ck •
Ellen Tufvesson • Leif Bjermer • Jonas Jo¨gi
Received: 21 August 2014 / Accepted: 30 September 2014 / Published online: 15 October 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract The severity of chronic obstructive lung disease
(COPD) is defined by the degree of flow limitation mea-
sured as forced expiratory volume in 1 s, which mainly
reflects impairment of large and intermediate airways.
However, COPD is primarily a small airways disease.
Therefore, better diagnostic tools are needed. Ventilation-
Perfusion (V/P) SPECT is a sensitive method to detect
obstructive lung changes but criteria for staging airway
obstruction are missing.
Purpose To define and validate criteria to stage COPD
using V/P SPECT.
Method 74 subjects (healthy non-smokers, healthy
smokers or with stable COPD) were included. All were
examined with V/P SPECT in a hybrid SPECT/CT system.
Spirometry was performed and patients were evaluated
with the clinical COPD questionnaire (CCQ). V/P SPECT
was interpreted independently. Preserved lung function (%)
was evaluated. The degree of airway obstruction on V/P
SPECT was graded according to newly-developed grading
criteria. The degree of airway obstruction was graded from
normal (0) to severe (3). The airway obstructivity-grade
and degree of preserved lung function were compared to
GOLD, CCQ and LDCT emphysema extent.
Results Obstructivity-grade (r = 0.66, P \ 0.001) and
the degree of preserved lung function (r = -0.70,
P \ 0.001) both correlated to GOLD. Total preserved lung
function decreased in relation to higher GOLD stage. There
was a significant difference between healthy controls and
apparently healthy long time smokers both regarding ob-
structivity-grade (P = 0.001) and preserved lung function
(P \ 0.001). Long-time smokers did not differ significantly
from GOLD 1 COPD patients (P = 0.14 and P = 0.55 for
obstructivity-grade and preserved lung function, respec-
tively). However, patients in GOLD 1 differed in ob-
structivity-grade from non-smoking controls (P = 0.02).
Conclusion Functional imaging with V/P SPECT enables
standardized grading of airway obstruction as well as
reduced lung function, both of which correlate with GOLD
stage. V/P SPECT shows that long-term smokers in most
cases have signs of ventilatory impairment and airway
obstruction not shown by spirometry.
Keywords Ventilation/Perfusion SPECT  Pulmonary
scintigraphy  Chronic obstructive pulmonary disease
(COPD)  Imaging interpretation criteria  Technegas
Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality. COPD is characterized
by airflow limitation and abnormal inflammatory response,
most often as a result of cigarette smoking [1, 2]. The
changes that occur in the lungs include increased airway
resistance due to airway fibrosis, inflammation and luminal
plugs, and increased compliance caused by parenchymal
destruction and loss of alveolar attachments. There are also
vascular changes due to inflammatory remodelling with
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progressive vascular occlusion and loss of vasculature in
areas with emphysematous destruction. Hence, COPD is a
heterogeneous condition and the clinical presentation,
pathophysiology, disease progression and response to
therapy vary between patients [3]. Comorbidities like heart
failure, lung cancer, pulmonary vascular disease, pulmon-
ary embolism (PE) and atherosclerosis are common [4, 5].
Today, COPD is diagnosed and graded by spirometric
indices like forced expiratory volume in 1 s (FEV1), forced
vital capacity (FVC) and their ratio [1]. FEV1 measures the
degree of airflow obstruction, predominantly in large and
intermediate airways, but provides no explanation of the
underlying pathophysiology [6]. It is therefore generally
accepted that FEV1 by itself cannot describe the com-
plexity of COPD and that FEV1 cannot be used in isolation
for optimal assessment and management of the disease [1,
7]. No acceptable diagnostic alternative has been
established.
The focus on individualized treatment in COPD is
growing and there is a need for better ways to categorize
patients into different phenotypes to be able to optimize
therapy, follow and predict disease progression and mea-
sure response to therapy [3]. Different imaging modalities
are generating interest within the field of COPD [8].
Tomographic pulmonary scintigraphy (ventilation/per-
fusion single photon emission computed tomography: V/P
SPECT) is a nuclear medicine investigation that gives a
3-dimensional functional map of the ventilation and per-
fusion of the lungs and shows how these are affected by
disease. Its primary use is in the diagnosis and follow-up of
pulmonary embolism (PE) [9–11]. The introduction of
ultra-fine aerosols has expanded the field of application for
V/P SPECT and airway obstruction is no longer considered
as a general problem for PE diagnosis, which was the case
for previous aerosols with larger particle size [12]. More-
over, V/P SPECT has been shown to have applications in
COPD and to be more sensitive than computed tomography
(CT) and FEV1 in detecting early airway changes [13–15].
It has also been shown that V/P SPECT can be used to
differentiate between healthy controls and COPD patients
and to grade the degree of airway obstruction in COPD [13,
16]. Furthermore, it can be used to semi-quantitatively
assess the degree of lung function reduction in obstructive
lung disease and PE [13, 17]. The grading of airway
obstruction in previous studies was, however, not
standardized.
In this study, we aimed to develop a standardized way to
grade COPD using V/P SPECT based on the distribution
pattern of ultra-fine aerosol in the lungs. Moreover, we
wanted to validate the COPD grading system and compare
it to the Global initiative for obstructive lung disease
(GOLD) classification in patients with various degrees of
COPD, apparently healthy long-term smokers and healthy
non-smokers.
Patients and methods
This prospective study was performed with approval from
the Regional Ethical Committee in Lund, Sweden. All
patients gave their informed consent of participation.
55 patients with COPD (GOLD 1, 4 patients; GOLD 2, 37
patients; GOLD 3, 13 patients; GOLD 4, 1 patient) and 14
apparently healthy current or former long-term smokers were
recruited at the department of Respiratory Medicine and
Allergology, Ska˚ne University Hospital, Lund, Sweden. Five
patients without any history of smoking or obstructive lung
disease were also included as controls. These were recruited
from patients referred for suspected PE that did not show any
signs of vascular obstruction. Patient characteristics are
shown in Table 1. All patients were over the age of 40 years,
clinically stable and, in the case of COPD patients, without
any exacerbations during the past 4 weeks prior to inclusion.
Drug therapy was kept unchanged. All subjects were assessed
clinically and by the clinical COPD questionnaire (CCQ), to
investigate their functional and mental state and the degree of
symptoms [18]. Spirometry was performed to measure FEV1,
FVC, and body plethysmography was used to measure TLC
(total lung capacity) and RV (residual volume). FEV1 %,
FVC %, RV % and TLC % values were calculated as a per-
centage of the predicted normal values [19].
The participants’ degree of obstructive lung disease was
also categorized in accordance with GOLD [1]. All sub-
jects except the five non-smoking controls underwent a
combined V/P SPECT/low dose CT (LDCT) examination
within 48 h of spirometry. The five controls were examined
with V/P SPECT but not LDCT. The data from the V/P
SPECT examination were then used to assess the degree of
airway obstructivity (graded 0–3), in accordance with a
predefined grading system developed at the department of
Clinical physiology and nuclear medicine, Ska˚ne, Lund
Table 1 Patient characteristics among healthy controls, apparently
healthy long-term smokers and patients with COPD
Controls Healthy smokers COPD
N 5 14 55
Gender (m/w) 1/4 7/7 30/25
Age (years) 63 ± 5 69 ± 3 68 ± 5
Pack-years 0 ± 0 32 ± 6 42 ± 24
BMI (kg/m2) 24 ± 4 26 ± 4 25 ± 5
Values are mean ± SD
BMI body-mass index
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University hospital. How much of the total lung function
that was preserved (preserved ventilation and perfusion)
was also evaluated semi-quantitatively and expressed in
percent (%) of the estimated total lung function.
Clinical COPD questionnaire
The CCQ was used to measure symptoms and functional
state. It has been validated for studies of clinical control in
COPD patients [18]. The 10-item CCQ is self-administered
and patients are instructed to recall symptoms experienced
during the last 7 days.
Spirometry
A body plethysmograph (MasterScreen Body/Diffusion;
Viasys Healthcare) was used to measure FEV1, FVC, TLC
and RV. Spirometry was quality controlled in accordance
with the American Thoracic Society guidelines [20].
LDCT/V/P SPECT protocol
A combined SPECT/CT (Precedence, Philips, Best, Neth-
erlands) system with a dual head gamma camera combined
with a 16 slice CT (Brilliance) was used for the V/P
SPECT/LDCT examinations. The procedure started with a
CT overview image and continued with diagnostic low
dose CT, (120 kV, 20 mAs/slice, 16 9 1.5 collimator, 0.5-
s rotation time, and pitch of 0.813). The slice thickness was
5 mm and the incremental value 5 mm. We used filtered
back projection to reconstruct LDCT images.
CT was not used for attenuation correction but to co-
localize the morphological and functional changes visual-
ized in either of the two modalities and were obtained
during tidal breathing. CT was also used for emphysema
extent quantification, which was done by one chest radi-
ologist specialised in CT of the thorax. CT emphysema
grading was visual and semi-quantitative and expressed the
total amount of emphysema as a 10th-percentile of the total
lung volume. The system used to score the extent of
emphysema was an adaption of the four grade scale, used
in previous studies, to an estimated 10th-percentile scale
[21, 22]. All transversal sections above the level of the
diaphragm were assessed. Each section was evaluated
individually and graded to the 10th percentage area that
demonstrated emphysematous changes. The scores from all
the sections were then added and this number was finally
divided with the total number of sections to get the per-
centage of the total lung volume affected by emphysema.
The protocol for V/P SPECT followed LDCT
examination.
V/P SPECT imaging was performed in accordance with
the recommendations of the European Association of
Nuclear Medicine (EANM) [23, 24]. Briefly, a large-field-
of-view dual-head gamma-camera with a low energy, all-
purpose collimator was used. Technegas (Cyclomedica
Ltd, Lucas Heights, Australia) was inhaled until 30 MBq
had reached the lungs, and ventilation tomography fol-
lowed. After that, with the patient in a carefully maintained
supine position, 120 MBq 99mTc-MAA was slowly
injected intravenously. Then, perfusion tomography was
performed. Acquisition was performed in a 64 9 64
matrix, zoomed to a pixel size of 6.8 mm with 128 pro-
jections over 360 degrees. Sixty-four steps, each of 10 s
duration, were used for the ventilation study, and 64 steps
of 5 s duration were used for the perfusion study. Recon-
struction was performed using ordered subsets expectation
maximization with 8 subsets and 2 iterations. All exam-
inations were performed in a department fulfilling the
requirements of ISO/IEC 17025.
Evaluation of V/P SPECT images
V/P SPECT was evaluated by two experienced nuclear
medicine physicians, blinded to other information, and inter-
preted according to the guidelines of the EANM [10, 23].
















Fig. 1 Schematic presentation of the obstructive lung disease grading
system and correlating representative V/P SPECT images that shows
different degrees of airway obstruction on frontal slices. 0 Normal,
even distribution of Technegas with good peripheral penetration and
without accumulation in large or small airways. 1 Mild airway
obstruction, slightly uneven distribution with some deposition of
aerosol in small and intermediate airways. Only minor areas with
reduced peripheral penetration are observed. 2 Moderate airway
obstruction, deposition of Technegas in intermediate and large
airways, diminished peripheral penetration with maximum accumu-
lation in central half of the lung. 3 Severe airway obstruction, central
deposition in large airways with severely impaired penetration of
Technegas and major areas with reduced or abolished function
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(1) Unevenness of Technegas distribution and (2) dis-
tribution of hot-spots (i.e., deposition of inhaled radio-
pharmaceutical in major and intermediate conductive
airways or/and peripheral hot-spots (i.e., focal deposition
of Technegas in distal airways) [12, 13]. Thereafter, ven-
tilation and perfusion images were assessed together.
Regions with reduced/absent ventilation and/or perfu-
sion were estimated and quantified [17].
Grading airway obstruction and lung function with V/P
SPECT
Qualitatively, the degree of obstructive lung disease was
visually graded according to a predefined 4-point scale
based on the ventilatory impairment shown by the distri-
bution pattern of Technegas in the airways. The scale was
as follows: Fig. 1.
0. Normal: even distribution of Technegas with good
peripheral penetration and without accumulation in
large or small airways.
1. Mild airway obstruction: slightly uneven distribution
with some deposition of aerosol in small and interme-
diate airways. Only minor areas with reduced periph-
eral penetration are observed.
2. Moderate airway obstruction: deposition of Technegas
in intermediate and large airways, diminished periph-
eral penetration with maximum accumulation in the
central half of the lung.
3. Severe airway obstruction: central deposition in large
airways with severely impaired penetration of Tech-
negas and major areas with reduced or abolished
function.
In addition, total preserved lung function was quantified
semi-quantitatively and described in % of the total esti-
mated lung volume. To be regarded as an area with fully
preserved lung function both ventilation and perfusion had
to be normal and matched.
Ventilation/perfusion defects were quantified by count-
ing segments or sub-segments showing complete or
reduced ventilation and/or perfusion defects and were
expressed in % of the total lung parenchyma [13, 17, 25].
A segmental reduction or a sub-segmental total defi-
ciency of function was attributed 1-point, and segmental
total deficiency 2 points. Each lung comprises 9 segments,
representing 18 points. Defects were expressed as points,
which after division by 36 give the percentage of the lung
that has impaired function. Thus, a theoretical total loss of
function would yield 36 points.
The total sum of the V/P defects was used to estimate
the extent of total reduction in lung function [17]. The
physicians graded the degree of obstructive disease, if
present, as mild (approximately affecting \20 % of the
lung function), moderate (20–50 % approx.) or severe
([50 %). The extent of matched (reduction in
V = reduction in P), mismatched (P \ V) and reverse
mismatched (V \ P) defects were expressed as a percent-
age of the total lung volume. The sum of these was used to
estimate the extent of total reduction in lung function. V/P
SPECT images were finally reviewed according to clinical
routine assessing the presence of PE, CHF or other car-
diopulmonary disease [11, 12, 24, 26]. The final interpre-
tation of V/P SPECT was based on a consensus reading.
Statistics
The non-parametric Spearman rank correlation test was
used to calculate correlations between V/P SPECT, CCQ,
spirometry and emphysema extent on LDCT. The two-
tailed Mann–Whitney U test was used for comparison of
differences between groups. Statistical analysis was per-
formed using GraphPad Prism 6.0c (GraphPad Software,
CA, USA). The null hypothesis was rejected when
P \ 0.05.
Results
Patient characteristics are shown in Table 1. All patients
successfully underwent all study examinations. Table 2
shows the V/P SPECT obstructivity-grade and preserved
lung function data, the emphysema extent on LDCT, spi-
rometry values and functional state evaluation through
CCQ. Table 3 gives the Spearman’s correlations between
them.
There was a moderate to strong correlation between the
obstructivity-grade (r = 0.66, P \ 0.001) and the degree
of preserved lung function (r = -0.70, P \ 0.001) com-
pared to GOLD grade. Obstructivity-grade and the degree
of preserved lung function for all groups are shown in
Fig. 2. In Fig. 3, V/P SPECT images demonstrate a dif-
ferent degree of obstructivity in transversal, sagittal and
frontal projections.
There was a significant difference between healthy
controls and apparently healthy long-term smokers
regarding V/P SPECT obstructivity-grade (P = 0.001) and
preserved lung function (P \ 0.001). Long-term smokers
did not, however, differ significantly from COPD patients
in GOLD 1 (P = 0.14 and P = 0.55 for obstructivity-
grade and preserved lung function, respectively). Patients
in GOLD 1 differed significantly in obstructivity-grade
from healthy non-smoking controls (P = 0.02), though.
While 4 out of 5 (80 %) of the healthy controls were
regarded as normal concerning airway obstructivity grade,
only 1 out of the 14 (7 %) apparently healthy long-term
smokers was regarded as completely normal (graded as 0).
94 Ann Nucl Med (2015) 29:91–99
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Among the COPD patients in GOLD 1 and 2 there were
three individuals that had nearly normal ventilation
according to V/P SPECT (obstructive-grade \1; 1 patient
in GOLD 1 and 2 patients in GOLD 2). These 3 patients
also showed an almost normal preserved lung function with
regard to ventilation and perfusion.
Regarding emphysema extent measured on LDCT, there
was only weak correlation to GOLD (r = 0.44;
P \ 0.001). The only significant difference observed
between patient groups regarding emphysema was between
patients in GOLD 3 compared to GOLD 2 (P = 0.05).
Apparently healthy long-time smokers and GOLD 1,
GOLD 1 and GOLD 2 COPD patients did not show sig-
nificant differences in emphysema extent (P = 0.35 and
0.68, respectively).
Moderate correlations were seen between functional
state measured by CCQ, and obstructivity-grade, preserved
lung function, GOLD and FEV1, respectively (Table 3).
In 14 of the 55 patients with COPD (25 %), a perfusion
pattern consistent with left heart failure (LHF) and
pulmonary congestion was found in V/P SPECT images
[26]. All patients with signs of LHF were in GOLD 2 or
higher. V/P SPECT also identified vascular changes (V/P
mismatch) in 16 cases (23 %) among the 69 subjects who
were either long-time smokers or had COPD.
Discussion
This study shows that V/P SPECT grading of obstructive
lung disease can be standardized based on ventilation
patterns in apparently healthy smokers and known COPD
patients. Based on the penetration of Technegas from the
center to the periphery of the lungs, four typical patterns
were used to grade the degree of obstructive airway disease
by two reviewers (Figs. 1, 3). A moderate to strong cor-
relation was found when the V/P SPECT obstructivity-
grade was compared to GOLD classification (Fig. 2).
Interestingly, apparently healthy smokers also showed
ventilatory impairment and obstructive patterns on V/P
Table 2 V/P SPECT, LDCT, CCQ and Spirometry data among healthy controls, apparently healthy long-term smokers and patients with various
degrees of COPD
Controls Healthy smokers COPD (GOLD grade)
1 2 3 4
N 5 14 4 37 13 1
V/P SPECT
Obstructivity grade 0.0 (0.0–0.25) 1.25 (1.0–2.0) 1.75 (0.75–2.0) 2.0 (2.0–2.5) 3.0 (2.75–3.0) 3.0
Preserved lung function (%) 100 (97.5–100) 80 (69–85) 65 (47.5–94) 50 (40–65) 30 (25–40) 15
CT
Emphysema extent (%) N/A 0 (0–5) 2.5 (0–31) 5 (0–10) 20 (5–40) 10
CCQ 0 (0–1) 2.5 (1.5–5.5) 10 (2–20) 15 (12–22) 21 (13–26) 31
Spirometry
FEV1 % 99 (94–118) 102 (92–106) 88 (64–93) 62 (55–72) 41 (34–48) 28
FVC % 110 (100–114) 96 (85–111) 107 (79–125) 99 (80–105) 81 (75–108) 74
RV % 129 (110–134) 120 (105–136) 125 (115–135) 152 (138–170) 202 (162–229) 276
TLC % 111 (104–120) 108 (98–116) 111 (99–116) 114 (101–121) 118 (112–128) 155
Values are median (interquartile range)






* P \ 0.05, ** P \ 0.01,
*** P \ 0.001





Obstructivity grade -0.94*** 0.56*** 0.58***
Preserved lung function (%) -0.94*** -0.59*** -0.61***
Emphysema extent CT (%) 0.56*** -0.59*** 0.32**
GOLD 0.66*** -0.70*** 0.44*** 0.63***
CCQ 0.58*** -0.61*** 0.32**
FEV1 % pred -0.64*** 0.63*** -0.42*** -0.68***
FVC % pred -0.16 0.14 0.09 -0.32**
FEV1/FVC -0.63*** 0.64*** -0.60*** -0.60***
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SPECT not significantly different from those seen in
GOLD 1, COPD patients. Although a normal FEV1 value
on spirometry testing excludes COPD, we still observed
various degrees of airway obstruction among the appar-
ently healthy long-term smokers. It is known that spirom-
etry measures do not always correlate to the real degree of
airway obstruction and clinical symptoms [27, 28]. The
pathology of COPD manifests in the small airways that do
not normally contribute to airflow resistance measured by
FEV1. Therefore, spirometry detects changes only after
airway obstruction has developed substantially. Similar
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A BFig. 2 V/P SPECT Lung
obstructivity grade (a) and
preserved lung function
(b) among healthy controls,
apparently healthy long-time
smokers and patients with
various degrees of COPD
(GOLD 1–4). ns no significance,
*P \ 0.05, **P \ 0.01,
***P \ 0.001. Bars represent
median values and whiskers
interquartile range
Fig. 3 VP SPECT images showing different degrees of airway obstruction in transversal, frontal and sagittal projections
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Technegas and its relation to different grades of airway
obstructivity were shown by Pellegrino et al. [27]. The
authors suggested that the hot-spots mainly represented
exaggerated deposition of Technegas occurring in the air-
ways when narrowing is sufficiently severe to cause air
flow limitations during tidal expiration.
Although three of the non-smoking controls had a
completely normal ventilation/perfusion pattern on SPECT
it is interesting to note that all but one of the apparently
healthy long-term smokers (13/14) showed a typical
obstructive pattern on V/P SPECT. This supports the
opinion that spirometry is not sensitive enough to diagnose
small airway disease in COPD. Among GOLD 1 and 2
COPD patients only three patients showed an almost nor-
mal ventilation pattern. This highlights the potential of V/P
SPECT to detect early functional airway abnormalities that
precede the decline in FEV1.
The studies performed by Pellegrino et al. [27] showed
that expiratory flow limitations occurred across the lungs
well before expiratory flow reserve was abolished and that
methods based on mouth flow measurement are not sen-
sitive enough to detect expiratory flow limitations. The
results of the present study are consistent with the per-
ception that airflow limitations have different, distinct
aetiologies. Moreover, the extent of emphysema as mea-
sured by LDCT shows only weak correlation to GOLD
grade. The severity of airflow obstruction was not predicted
by the extent of emphysema. These results are in agree-
ment with Timmins et al. [29] who predominantly analysed
patients with GOLD 2 and 3.
In a study by Jobse et al. [15], where FEV1 did not
correlate to the degree of emphysema, small airways dis-
ease was predicted by the ventilation/perfusion pattern on
V/P SPECT. The results of the present study add to pre-
vious works by showing a method to characterize the
physiological phenotypes in COPD and healthy smokers
that might be clinically useful.
The preserved total lung function as quantified, by V/P
SPECT, also showed a strong correlation with the level of
obstructivity according to spirometry and GOLD (Fig. 2).
Comorbidities are frequent among patients with COPD
[4, 30, 31] and we have confirmed the high incidence
(25 %) of patients with a pattern typical for LHF and
pulmonary congestion. This is also in agreement with our
earlier findings [26]. Interestingly, all patients with signs of
LHF were in GOLD 2 or higher. In addition, altered ven-
tilation patterns add information regarding the functional
effects of inflammatory exudate, small airway remodelling
and mucus production.
The vascular response is often impaired in COPD patients
and this leads to a reduced ability to adapt to ventilatory
impairment by means of hypoxic vasoconstriction. In some
COPD patients coagulability is increased leading to perfu-
sion defects. Vascular defects (V/P mismatch) were a second
important finding in this study and were seen in 16 cases
(23 %) among the 69 subjects who were either long-term
smokers or had COPD. In our earlier studies we have had
the similar results [13]. The importance of the vascular
component has also been stressed previously by other
authors [32].
The use of V/P SPECT functional imaging in COPD
patients might serve as a new tool to clarify patient’s
symptoms and the heterogeneity of the disease. It may also
help diagnosing comorbidities that often coexist that may
have a significant impact on the prognosis. Today,
according to GOLD, spirometry is used to classify patients
with COPD and together with symptoms, to determine the
severity of the disease. The goals are to estimate its impact
on patients’ health status and the risk of future events.
Moreover, V/P SPECT allows the possibility of per-
forming the examination in the group of patients who are
experiencing chest pain or have frequent cough, which
could limit the possibility to perform spirometry success-
fully. Furthermore, the estimate of total lung function
might be of help in the choice of therapy as well as a
possible way to follow-up and estimate therapy results.
This needs to be further studied. Co-registration with CT
images allows superior insight into the anatomic localiza-
tion of lung dysfunction. However, as shown in animal
studies, CT is not sensitive enough to identify early
changes in COPD that can readily be visualized on V/P
SPECT [33]. As smoking cessation is the best treatment of
COPD, early detection is essential.
Strengths and limitations
One of the demonstrated strengths of this study was the
ability to categorize different degrees of obstructive lung
disease based on the ventilation/perfusion pattern in
apparently healthy smokers and known COPD patients.
The second strength is the possibility to visualize co-
morbidities frequently present in healthy smokers and
COPD patients and the possibility to describe total lung
function through estimation of ventilation and perfusion
impairment. Moreover, V/P SPECT is performed during
quiet breathing as opposed to spirometry. This may be a
methodological advantage.
There are limitations that need to be acknowledged
regarding the method of analysis. The estimation is semi-
quantitative and pattern recognition subjective. LDCT
reconstruction was filtered back-projection and no auto-
matic quantification was done. Further work must be
focused on development of an automated program that will
facilitate accurate objective quantification.
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Conclusion
The present study shows that V/P SPECT can be used for
standardized grading of airway obstruction and lung
function, which both correlate to GOLD classification.
Furthermore, this study shows that even in apparently
healthy long-term smokers, the majority have signs of
ventilatory impairment and airway obstruction on V/P
SPECT, not shown by spirometry or LDCT. This highlights
the potential of V/P SPECT with its high sensitivity to
detect early airway abnormalities.
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